Amneal Pharmaceuticals, Inc. (AMRX)

Market Cap	3.97B
Revenue (ttm)	2.93B
Net Income (ttm)	5.90M
Shares Out	314.36M
EPS (ttm)	0.02
PE Ratio	673.48
Forward PE	15.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,449,476
Open	12.37
Previous Close	12.33
Day's Range	12.32 - 12.72
52-Week Range	6.69 - 12.72
Beta	1.37
Analysts	Buy
Price Target	13.25 (+4.83%)
Earnings Date	Oct 30, 2025

About AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 8,300
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRX
• Website: https://www.amneal.com

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for AMRX stock is "Buy." The 12-month stock price target is $13.25, which is an increase of 4.83% from the latest price.

Price Target

$13.25

(4.83% upside)

Analyst Consensus: Buy